“…The next article in this issue, from Gardiner et al, delves into the discussion of laboratory developed tests (LDTs), assays that are more commonly performed in highly specialized hemostasis/thrombosis laboratories, and that fill an important niche for patient testing when there are no commercially available options approved by local regulatory authorities, or the commercial options are of substandard quality. 7 The manuscript provides important background context on differences in laboratory regulation in different parts of the world, and explores the challenges associated with increasing LDT regulation with potential impacts to patient care. The manuscript provides helpful tables that summarize studies that should be performed during the validation of a high-quality LDT.…”